We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
+13.35%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$2.6B
AUM Growth
-$20.1M
Cap. Flow
-$139M
Cap. Flow %
-5.36%
Top 10 Hldgs %
41.28%
Holding
99
New
18
Increased
10
Reduced
56
Closed
6

Top Buys

Rank Stock Value
1
IMVT icon
Immunovant
IMVT
+$49.3M
2
ALXO icon
ALX Oncology
ALXO
+$38.2M
3
OMER icon
Omeros
OMER
+$28.6M
4
TRIL
Trillium Therapeutics Inc.
TRIL
+$24.9M
5
ZYME icon
Zymeworks
ZYME
+$20.6M

Top Sells

Rank Stock Value
1
PRNB
Principia Biopharma Inc. Common Stock
PRNB
+$95.1M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$30.8M
3
STSA
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
+$23M
4
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
+$20.6M
5
CCXI
ChemoCentryx, Inc.
CCXI
+$16.2M

Sector Composition

Rank Sector Weight
1 Healthcare 80.25%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TPTX
1
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$213M 8.2%
2,442,297
-295,000
-11% -$20.6M
SPY icon
2
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$784B
$167M 6.44%
500,000
– –
FMTX
3
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
$166M 6.4%
3,379,373
– –
RVMD icon
4
Revolution Medicines
RVMD
$40.9B
$91.9M 3.53%
2,640,177
+3,516
+0.1% +$97.4K
BBIO icon
5
BridgeBio Pharma
BBIO
$16.1B
$85M 3.27%
2,265,762
-325,000
-13% -$10.2M
CCXI
6
DELISTED
ChemoCentryx, Inc.
CCXI
$76.7M 2.95%
1,400,000
-300,000
-18% -$16.2M
IWM icon
7
PUT
iShares Russell 2000 ETF
IWM
$80.2B
$74.9M 2.88%
500,000
– –
RNAM
8
DELISTED
Avidity Biosciences
RNAM
$69.5M 2.67%
2,514,546
-1
-0% -$29
SRNE
9
DELISTED
Sorrento Therapeutics, Inc.
SRNE
$66.9M 2.57%
6,000,000
-500,000
-8% -$4.58M
MYOK
10
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$61.3M 2.36%
450,000
-150,000
-25% -$15.9M
IMVT icon
11
Immunovant
IMVT
$8.11B
$57.6M 2.22%
+1,637,951
New +$49.3M
APLS
12
DELISTED
Apellis Pharmaceuticals
APLS
$56.3M 2.16%
1,866,108
-200,000
-10% -$5.98M
XLRN
13
DELISTED
Acceleron Pharma
XLRN
$56.3M 2.16%
500,000
-100,000
-17% -$9.96M
XBI icon
14
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.3B
$55.7M 2.14%
500,000
– –
YMAB
15
DELISTED
Y-mAbs Therapeutics
YMAB
$53.7M 2.06%
1,397,700
-176,983
-11% -$7.04M
ZYME icon
16
Zymeworks
ZYME
$1.67B
$53.6M 2.06%
1,150,000
+600,000
+109% +$20.6M
STOK icon
17
Stoke Therapeutics
STOK
$1.87B
$51.5M 1.98%
1,537,807
-163,485
-10% -$4.67M
OMER icon
18
Omeros
OMER
$863M
$50.5M 1.94%
5,000,000
+2,225,000
+80% +$28.6M
EIDX
19
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
$50.2M 1.93%
993,185
-62,117
-6% -$2.79M
MRTX
20
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$45.7M 1.76%
275,000
-225,000
-45% -$30.8M
VIE
21
DELISTED
Viela Bio, Inc. Common Stock
VIE
$44.5M 1.71%
1,585,000
+72,500
+5% +$2.57M
RETA
22
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$43.8M 1.69%
450,000
+50,000
+13% +$6.25M
TWST icon
23
Twist Bioscience
TWST
$5.69B
$38M 1.46%
500,000
-52,849
-10% -$3.29M
ALXO icon
24
ALX Oncology
ALXO
$262M
$36M 1.38%
+971,770
New +$38.2M
TRIL
25
DELISTED
Trillium Therapeutics Inc.
TRIL
$35.5M 1.37%
+2,500,000
New +$24.9M
1
2 3 4

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
CCA
Checchi Capital Advisers Beverly Hills, California $1.98B AUM 19.17% 1-Year Est. Return
LBC
Lowe Brockenbrough & Co Richmond, Virginia $2.01B AUM 22.05% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return

Cormorant Asset Management's Q3 2020 Portfolio in Review

As of Q3 2020, Cormorant Asset Management held 99 positions worth $2.6B, down 0.77% from $2.62B the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Cormorant Asset Management withdrew a net $139M in Q3 2020, closing 6 positions and reducing 56 holdings. Its most notable exit was Principia Biopharma Inc. Common Stock, an estimated $95.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, down from 82% a quarter earlier.

Against the trend, Cormorant Asset Management opened a new position in Immunovant worth $57.6M.

  • Cormorant Asset Management's largest Q3 2020 buy was Immunovant: 1,637,951 shares worth $57.6M.
  • Cormorant Asset Management added most to Omeros in Q3 2020, an estimated $28.6M increase.
  • Cormorant Asset Management's biggest Q3 2020 reduction was Mirati Therapeutics, Inc. Common Stock, cutting an estimated $30.8M.
  • Cormorant Asset Management fully exited Principia Biopharma Inc. Common Stock in Q3 2020, selling an estimated $95.1M.
  • Cormorant Asset Management's ten largest holdings make up 41% of its $2.6B portfolio in Q3 2020.
  • Cormorant Asset Management opened 18 new positions and closed 6 in Q3 2020.
  • Cormorant Asset Management's portfolio value fell 0.77% quarter-over-quarter to $2.6B.

Based on Cormorant Asset Management's 13F filing for Q3 2020, filed 16 Nov 2020.